ASCO & NEJM: AI plus ovarian suppression yields benefit in high-risk younger breast cancer patients
CHICAGO - Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian...



